Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Jacob P. Thyssena Department of Dermatology and Venersology, Bispebjerg Hospital, Copenhagen, DenmarkView further author information

Thomas Werfelb Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, GermanyView further author information

Sebastien Barbarotc Department of Dermatology, Nantes Université, Centre Hospitalier Universitaire de Nantes, Nantes, FranceView further author information

Hamish J.A Hunterd Department of Dermatology, Salford Care Organisation, part of the Northern Care Alliance NHS Foundation Trust, Salford, UKView further author information

Evangeline Piercee Eli Lilly and Company, Indianapolis, IN, USAView further author information

Luna Sune Eli Lilly and Company, Indianapolis, IN, USAView further author information

Lisa Cirrie Eli Lilly and Company, Indianapolis, IN, USAView further author information

Andrew S. Buchanane Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
View further author information

Na Luf Precision Statistics Consulting, Woodbury, MN, USAView further author information

Andreas Wollenbergg Department of Dermatology and Allergy, University Hospital, Ludwig Maximillian University, Munich, GermanyView further author information

show all

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date